aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine for GMP Process Development and for Potential Treatment of Severe Lung Diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine for GMP Process Development and for Potential Treatment of Severe Lung Diseases

aTyr Pharma (LIFE) Selects iMod.Fc Molecule as IND Candidate

November 11, 2015 7:37 AM EST

aTyr Pharma (NASDAQ: LIFE) announced that it has selected an Investigational New Drug (IND) Candidate based on an immuno-modulatory and fibro-modulating Physiocrine domain fused to an Fc region of a human antibody, iMod.Fc. The selected iMod.Fc molecule is intended to address patients with severe pulmonary diseases with an immune and fibrotic component.

"The molecule developed in our iMod.Fc discovery program represents a major breakthrough as the first engineered Physiocrine with advantageous pharmaceutical properties... More